De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial-Reference-Cited by-同舟云学术

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Published:2022-05 Issue:5 Volume:23 Page:625-635
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Nitz Ulrike,Gluz Oleg,Graeser Monika,Christgen Matthias,Kuemmel Sherko,Grischke Eva-Maria,Braun Michael,Augustin Doris,Potenberg Jochem,Krauss Katja,Schumacher Claudia,Forstbauer Helmut,Reimer Toralf,Stefek Andrea,Fischer Hans Holger,Pelz Enrico,zu Eulenburg Christine,Kates Ronald,Wuerstlein Rachel,Kreipe Hans Heinrich,Harbeck Nadia,von Schumann Raquel,Kuhn Walther,Polata Silke,Bielecki Wojciech,Meyer Ralf,Just Marianne,Kraudelt Susanne,Siggelkow Wulf,Wortelmann Heidi,Kleine-Tebbe Anke,Leitzen Lena,Kirchhof Heidrun,Krabisch Petra,Hackmann John,Depenbusch Reinhard,Gnauert Karsten,Staib Peter,Lehnert Antje,Hoffmann Oliver,Briest Susanne,Lindner Christoph,Heyl Volker,Bauer Leila,Uleer Christoph,Mohrmann Svjetlana,Viehstaedt Nicole,Malter Wolfram,Link Theresa,Buendgen Nana,Tio Joke

Funder

Roche

Bayer

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Management of early-stage human epidermal growth factor receptor 2-positive breast cancer;Pernas;JCO Oncol Pract,2021

2. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

3. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy;Houssami;Eur J Cancer,2012

4. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis;Broglio;JAMA Oncol,2016

5. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial;Gianni;Lancet Oncol,2012

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

2. ASO Author Reflections: Evolving Multidisciplinary Decision Making for Early-Stage, HER2-Positive Breast Cancer;Annals of Surgical Oncology;2024-09-09

3. Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer;Current Treatment Options in Oncology;2024-08-17

4. HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial;Clinical Cancer Research;2024-07-12

5. Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know;Clinical Breast Cancer;2024-06